Lipocalin-2 and calprotectin as stool biomarkers for predicting necrotizing enterocolitis in premature neonates.
Lipocalin-2 and calprotectin as stool biomarkers for predicting necrotizing enterocolitis in premature neonates.
复制标题
DOI：
10.1038/s41390-021-01680-7
复制
发表时间：
2022-01
影响因子：
3.6
通讯作者：
Beaulieu JF
中科院分区：
文献类型：
--
作者：
Thibault MP;Tremblay É;Horth C;Fournier-Morin A;Grynspan D;Babakissa C;Levy E;Ferretti E;Bertelle V;Beaulieu JF
坏死性小肠结肠炎（NEC）是新生儿重症监护室中早产儿面临的一个重大挑战，迄今为止，寻找可用于预测该疾病发展的指标的努力成果有限。在这项研究中，每天收集132名极低出生体重婴儿的粪便，这是一项多中心前瞻性研究，旨在研究粪便生物标志物预测NEC的潜力。8名婴儿（~6%）接受了3期NEC诊断。他们在诊断前10天收集的粪便被包括在内，并与14个非NEC对照相匹配，并通过ELISA检测8种生物标志物的定量。在所有可用的粪便样品中评价生物标志物，从而鉴定出脂质运载蛋白-2和钙卫蛋白是NEC发展前10天内两种最可靠的预测标志物。汇集每个婴儿的数据证实了在NEC临床诊断前1周单独和组合的脂质运载蛋白-2和钙卫蛋白的显著性。脂质运载蛋白-2和钙卫蛋白串联体代表了用于预测NEC发展的重要生物标志物特征。虽然还没有达到“完美的生物标志物”的标准，但它代表了迈向这一标准的第一步。粪便生物标志物可用于在诊断前一周以上预测极低出生体重儿的NEC发展。LCN 2被确定为预测NEC发展的一种新的稳健生物标志物，与CALPRO结合使用，可以识别出超过一半的极低出生体重婴儿发生NEC的病例。将更多的粪便标志物与LCN 2/CALPRO串联体如PGE 2组合可以进一步改进用于预测NEC发展的算法。
Necrotizing enterocolitis (NEC) is a major challenge for premature infants in neonatal intensive care units and efforts toward the search for indicators that could be used to predict the development of the disease have given limited results until now. In this study, stools from 132 very low birth weight infants were collected daily in the context of a multi-center prospective study aimed at investigating the potential of fecal biomarkers for NEC prediction. Eight infants (~6%) received a stage 3 NEC diagnosis. Their stools collected up to 10 days before diagnosis were included and matched with 14 non-NEC controls and tested by ELISA for the quantitation of eight biomarkers. Biomarkers were evaluated in all available stool samples leading to the identification of lipocalin-2 and calprotectin as the two most reliable predicting markers over the 10-day period prior to NEC development. Pooling the data for each infant confirmed the significance of lipocalin-2 and calprotectin, individually and in combination 1 week in advance of the NEC clinical diagnosis. The lipocalin-2 and calprotectin tandem represents a significant biomarker signature for predicting NEC development. Although not yet fulfilling the “perfect biomarker” criteria, it represents a first step toward it. Stool biomarkers can be used to predict NEC development in very low birth weight infants more than a week before the diagnosis. LCN2 was identified as a new robust biomarker for predicting NEC development, which used in conjunction with CALPRO, allows the identification of more than half of the cases that will develop NEC in very low birth weight infants. Combining more stool markers with the LCN2/CALPRO tandem such as PGE2 can further improve the algorithm for the prediction of NEC development.
登录
查看更多内容
影响因子：
6.2
作者：
Cho, Steven X.;Berger, Philip J.;Nold-Petry, Claudia A.;Nold, Marcel F.
通讯作者：
Nold, Marcel F.
影响因子：
3.7
作者：
Chassaing B;Srinivasan G;Delgado MA;Young AN;Gewirtz AT;Vijay-Kumar M
通讯作者：
Vijay-Kumar M
影响因子：
2.5
作者：
Gollin, Gerald;Stadie, Derek;Angeles, Danilyn
通讯作者：
Angeles, Danilyn
影响因子：
2.9
作者：
MacQueen, B. C.;Christensen, R. D.;Lowe, J.
通讯作者：
Lowe, J.
DOI：
10.1016/j.pathophys.2013.11.009
发表时间：
2014-02-01
期刊：
Pathophysiology : the official journal of the International Society for Pathophysiology
影响因子：
--
作者：
Huda, Shehzad;Chaudhery, Shabnum;Pramanik, Arun
通讯作者：
Pramanik, Arun